Sherbrooke Park Advisers LLC Invests $330,000 in AtriCure, Inc. (NASDAQ:ATRC)

Sherbrooke Park Advisers LLC acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,792 shares of the medical device company's stock, valued at approximately $330,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ATRC. Franklin Resources Inc. raised its holdings in shares of AtriCure by 0.9% in the 3rd quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock valued at $1,569,000 after purchasing an additional 484 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of AtriCure by 1.8% in the 4th quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock valued at $414,000 after purchasing an additional 265 shares in the last quarter. KBC Group NV raised its holdings in shares of AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after purchasing an additional 932 shares in the last quarter. R Squared Ltd acquired a new stake in shares of AtriCure in the 4th quarter valued at $89,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of AtriCure in the 4th quarter valued at $60,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.50% of the stock is currently owned by insiders.

AtriCure Stock Performance

AtriCure stock traded down $0.10 during midday trading on Friday, hitting $32.71. 330,069 shares of the company's stock were exchanged, compared to its average volume of 650,988. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -34.43 and a beta of 1.57. The firm's 50 day simple moving average is $32.38 and its 200 day simple moving average is $34.80.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The company had revenue of $123.62 million for the quarter, compared to the consensus estimate of $122.92 million. During the same period last year, the firm posted ($0.28) EPS. AtriCure's revenue for the quarter was up 13.5% on a year-over-year basis. Equities research analysts predict that AtriCure, Inc. will post -0.6 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ATRC. Wall Street Zen upgraded shares of AtriCure from a "hold" rating to a "buy" rating in a report on Saturday. Stifel Nicolaus increased their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. UBS Group dropped their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Needham & Company LLC dropped their target price on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. dropped their target price on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, March 27th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $50.67.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.